anastrozole / Generic mfg. - LARVOL DELTA

Anastrozole modulates mitochondrial activity via Inhibitory action on mitochondrial permeability transition pore opening : An Initial Perspective on repurposive drug therapeutic. (SSIEM 2023) - No abstract available

Myositis

Anastrozole modulates mitochondrial activity via Inhibitory action on mitochondrial permeability transition pore opening : An Initial Perspective on repurposive drug therapeutic. (SSIEM 2023) - No abstract available

Myositis

Anastrozole modulates mitochondrial activity via Inhibitory action on mitochondrial permeability transition pore opening : An Initial Perspective on repurposive drug therapeutic. (SSIEM 2023) - No abstract available

Myositis

Anastrozole modulates mitochondrial activity via Inhibitory action on mitochondrial permeability transition pore opening : An Initial Perspective on repurposive drug therapeutic. (SSIEM 2023) - "Cyclosporin A, selected as positive and/or reference to compare with the target compound anastrozole. Mitochondriopathies account for majority of the common neurometabolic and neuromuscular disorders. No definitive therapy that directly modulates the function of mitochondria either by increasing the proportion of healthy mitochondria or by modulating the effects of mutated variants. Anastrozole seems to be a promising agent in ameliorating the in- vitro phenotype by regulating the activity across the mtPTP."

CNS Disorders • Genetic Disorders • Metabolic Disorders • CASP3 • PPIF

Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Functionalized nitrogen- and chalcogen-containing heterocyclic compounds as aromatase inhibitors: Design, synthesis and biological evaluation. (PubMed, Eur J Med Chem) - "Among non-steroidal aromatase inhibitors (NSAIs), letrozole and anastrozole are well-established treatments. Several compounds displayed nanomolar inhibitory activity, with potencies approaching that of letrozole in vivo, while maintaining favorable selectivity against other steroidogenic enzymes. Notably, benzoselenazolinone 75 emerged as the most promising candidate, exhibiting potency comparable to letrozole with improved in vitro selectivity, thereby justifying further evaluation in vivo."

Journal • Breast Cancer • Oncology • Solid Tumor

A randomized phase III study of first-line saruparib (AZD5305) plus camizestrant vs CDK4/6i plus physician's choice endocrine therapy or CDK4/6i plus camizestrant in patients with HR+/HER2− advanced breast cancer with BRCA1/BRCA2/PALB2 mutations (EvoPAR-Breast01) (DGHO 2025) - P3 | "Participants will be randomized 2:2:1 to receive saruparib plus camizestrant, physician's choice CDK4/6i (abemaciclib, ribociclib, or palbociclib) plus physician's choice ET (fulvestrant, letrozole, anastrozole, or exemestane), or physician's choice CDK4/6i plus camizestrant, respectively. Overall survival (OS) is a secondary endpoint. Approximately 500 participants will be randomized."

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • BRCA1 • BRCA2 • CDK4 • HER-2 • HRD • PALB2

First-in-human evaluation of IL2RG blockade in patients with severe aplastic anemia that is refractory to or relapsed on immunosuppressive therapy (ASH 2025) - "Given that lymphocyte development, proliferation, and activity aremediated in large part by gamma chain (gc) cytokines (IL2, IL4, IL7, IL9, IL15, IL21), which share a commonreceptor subunit (interleukin 2 receptor subunit gamma; IL2RG), IL2RG blockade may provide an novelmeans to suppress pathogenic T cell responses in T cell-mediated diseases, like AA. Data from this first-in-human evaluation of REGN7257 in patients with IST-refractory or IST-relapsed SAA show that IL2RG blockade was generally well-tolerated with observed AEs being generallyconsistent with the underlying disease. Reductions in lymphocytes and changes in serum cytokines andinflammatory/effector molecules were consistent with drug activity. One patient achieved a partialhematologic response that waned as drug cleared, but returned with retreatment."

Clinical • First-in-human • P1 data • Anemia • Aplastic Anemia • Febrile Neutropenia • Immunology • Infectious Disease • Neutropenia • Thrombocytopenia • CD8 • IL15 • IL2 • IL21 • IL2RG • IL4 • IL7 • IL9

Microbubbles In the Pericardial Space: An Unusual Echocardiographic Finding (AHA 2025) - "She was then started on Anastrozole and discharged to rehab with close follow up with oncology.Pneumopericardium is most often related to trauma, barotrauma, or procedures such as pericardiocentesis, pacemaker placement, or esophagectomy...Given the high mortality of unrecognized pneumopericardium and its potential for tamponade, early recognition of intrapericardial bubbles is critical. This case expands the differential diagnosis of this rare echocardiographic finding and highlights the importance of malignancy as an underlying etiology."

Asthma • Breast Cancer • Gastrointestinal Disorder • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Infectious Disease • Mood Disorders • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Tuberculosis • ER • PGR

Pulmonary Embolism Presenting with Classical S1Q3T3 Pattern on Electrocardiogram: Implications for Hemodynamic Instability (AHA 2025) - "A score > 8 is associated with worsened clinical outcomes, experts agree that evidence of RV failure warrants escalation of therapy beyond anticoagulation, including fibrinolytics and thrombectomy.Case:A 77-year-old female with medical history of Breast Cancer on anastrozole, Hypertension and recent left total knee arthroplasty (postoperative day 17) on Aspirin twice daily for prophylaxis...PE was suspected and a CTA confirmed a large saddle PE involving both main pulmonary arteries, with signs of RV strain, including RV dilation and contrast reflux into the IVC.Despite initiation of IV heparin, the patient developed worsening hypotension and was started on norepinephrine and systemic thrombolysis with tPA...ECG findings, especially when interpreted using scoring systems like the Daniel Score, can provide valuable insight into disease severity and prognosis. Clinicians should maintain a high index of suspicion and prioritize early diagnostic imaging and intervention..."

Breast Cancer • Cardiovascular • Hypertension • Hypotension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

COMPARISON OF CARDIOTOXIC EFFECTS BETWEEN AIs AEROMATASE INHIBITORS) AND SERMs (SELECTIVE ESTROGEN RECEPTOR INHIBITORS): A PHARMACOVIGILANCE ANALYSIS (AHA 2025) - "We included Anastrozole, Letrozole, and Exemestane for AIs and Raloxifene, Tamoxifen, Fulvestrant, and Toremifene for SERMs. AIs are observed to be associated with higher rates of CV AEs compared to SERMs. Further studies are warranted to establish the CV risk profile of these agents."

Adverse events • Breast Cancer • Developmental Disorders • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Solid Tumor • ROR1

Clinical Study of Fluzoparib Combined with Dalpiciclib and Endocrine Neoadjuvant Therapy for gBRCA-Mutated HR+/HER2- Early-Stage Breast Cancer (ChiCTR) - P=N/A | N=30 | Not yet recruiting | Sponsor: Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital

New trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • BRCA1 • BRCA2 • HER-2

The Breast Is Not History: Exploring a Rare Case of Metastatic Breast Cancer (MBC) to the Rectum (ACG 2025) - "Anastrozole was switched to fulvestrant (ER antagonist) and ribociclib (cyclin dependent kinase 4/6 inhibitor, held 3 months later due to rash and drug related pneumonitis). Biopsy results showing breast cancer metastases was unexpected given prior treatment and maintenance on anastrozole. The histologic findings guided transition to targeted systemic therapy, which highlights a new role of endoscopy in guiding MBC treatment.Figure: Figure 1: Flexible sigmoidoscopy images of nodular mucosa in rectum"

Clinical • Metastases • Breast Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Infectious Disease • Oncology • Pneumonia • Solid Tumor • ER • PGR

Exceptional Response to Pembrolizumab in Metastatic ER+/HER2- Breast Cancer With Liver Metastases: A Case Report and Literature Review. (PubMed, Case Rep Oncol Med) - "She was treated with neoadjuvant anastrozole, modified radical mastectomy, adjuvant chemotherapy, radiation, and continued endocrine therapy...The disease progressed on fulvestrant and palbociclib, but switching to carboplatin, gemcitabine, and pembrolizumab led to rapid improvement: liver function normalized and imaging showed near-complete response within 3 months...This case explains the potential role of ICIs in HR+/HER2- breast cancer with unusually high PD-L1 expression. It underscores the importance of biomarker-driven treatment and supports expanding PD-L1 testing to better identify patients who may benefit from immunotherapy in this traditionally resistant subtype."

IO biomarker • Journal • Breast Cancer • Hematological Disorders • Hepatocellular Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PD-L1 • PGR

Deceptive Lesions: Breast Carcinoma Presenting as a Splenic Metastasis With Gastric Wall Invasion (ACG 2025) - "This case highlights the importance of considering breast cancer in atypical presentations involving the spleen or gastrointestinal tract and highlights the critical role of immunohistochemistry in establishing the diagnosis.Case Description/ A 66-year-old woman with a history of ER+/PR–/HER2+ invasive ductal carcinoma (IDC) of the breast, diagnosed in 2017, was treated with neoadjuvant TCHP, partial mastectomy, adjuvant trastuzumab, pertuzumab, radiation, and anastrozole. She had recurrence of her breast cancer in 2021 and was switched from anastrozole to exemestane...Physicians should remain vigilant for atypical metastatic patterns in breast cancer survivors. Early recognition and multidisciplinary management are crucial, even when prognosis is poor.Figure: Figure 1: EGD showing a friable mass in the gastric fundusFigure: Figure 2: MRI showing a large splenic mass with invasion into the gastric wall"

Breast Cancer • CNS Disorders • Gastrointestinal Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Renal Disease • Septic Shock • Solid Tumor • CDX2 • GATA3 • HER-2 • PGR

Ribociclib-Induced Liver Injury: A Rare Complication of HR-Positive, HER2-Negative Metastatic Breast Cancer Treatment (ACG 2025) - "Her anastrozole was held due to concern for possible contribution...She was treated with a high-dose prednisone taper for two months with normalization of her liver function. Our case report demonstrates grade 1 DILI with grade 4 AST and ALT elevation due to ribociclib, an uncommon culprit of DILI...Management of CDK4/6 DILI is poorly described, with only 40% of cases treated with steroids. Our case report demonstrates normalization of liver function with a course of steroids, supporting the use of steroids in patients with CDK4/6 inhibitor DILI."

Metastases • Addiction (Opioid and Alcohol) • Breast Cancer • Fatigue • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Liver Failure • Oncology • Solid Tumor • HER-2

HEALING TURNED HARMFUL: RIBOCICLIB-INDUCED ORGANIZING PNEUMONIA (CHEST 2025) - "CASE PRESENTATION: A 61-year-old woman with metastatic breast cancer, recurrent malignant left-sided pleural effusion, and a history of pulmonary embolism on apixaban, presented with worsening dyspnea and productive cough, limiting daily activities...Given her immunosuppression, she received intravenous cefepime with symptomatic improvement at the time.On re-presentation, she was again hypoxic, requiring oxygen...Medication review showed she was on ribociclib, anastrozole, and denosumab. Recognizing organizing pneumonia as a known, but rare, adverse effect of ribociclib, the drug was discontinued and prednisone (1 mg/kg/ day) was initiated. Meropenem was initially continued empirically but subsequently discontinued following a multidisciplinary consensus that organizing pneumonia was the likely diagnosis.Her oxygen requirements decreased with corticosteroid therapy, and follow-up imaging after three days showed improved aeration... This case highlights the importance of..."

Breast Cancer • Cognitive Disorders • Cough • Fibrosis • Immunology • Infectious Disease • Interstitial Lung Disease • Pneumonia • Pulmonary Embolism • Rheumatology • Solid Tumor

Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes (ESMO 2025) - "Methods Pts with HR+/HER2− EBC were randomized 1:1 to RIB (400 mg/d; 3 weeks on/1 week off for 3 y) + NSAI (letrozole 2.5 mg/d or anastrozole 1 mg/d for 5 y) or NSAI alone. Men and premenopausal women received goserelin...Conclusions In this 5-year landmark analysis with mature efficacy data, RIB + NSAI reduced the risk of invasive and distant disease recurrence compared with NSAI alone, including in pts with high-risk N0 disease. A positive trend for OS in favor of RIB + NSAI continues to emerge."

Clinical • Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer. (PubMed, ESMO Open) - "Xentuzumab + abemaciclib + ETs demonstrated manageable tolerability and promising efficacy, especially in patients with breast cancer and non-visceral metastases."

Journal • P1 data • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CCND1 • HER-2 • IGF1 • MCL1

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer (clinicaltrials.gov) - P=N/A | N=5087 | Recruiting | Sponsor: Pfizer | Active, not recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

DEVELOPMENT OF ILD SECONDARY THE USE OF ABEMACICLIB (CHEST 2025) - "She subsequently received chemotherapy and was started on anastrozole plus Abemaciclib in February 2023...At discharge, she received prednisone and TMP/SMX with follow-up with pulmonology in the following weeks...performed a large-scale evaluation cancer report regarding abemaciclib and palbociclib showing an increased risk of developing ILD with onset of symptoms 1-2 months after the initiation of treatment.(3) Imaging 6 months after the patient's first dose of abemaciclib showed no findings of ILD (Figure 1)... Pneumonitis and ILD should be suspected when a patient on Abemaciclib develops respiratory symptoms and it should be promptly stopped and further investigated and treated with steroids if appropriate."

Breast Cancer • Cough • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Infectious Disease • Interstitial Lung Disease • Pneumonia • Solid Tumor • CDK4 • CDK6 • HER-2

Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments. (PubMed, Cancer) - "These results support prior research demonstrating an association between severe side-effect bother, as reported on responses to the GP5 item, and ETD among patients with newly diagnosed multiple myeloma. The consistent association between GP5 responses and ETD suggests the GP5's ability to capture how well patients tolerate treatment, especially when side-effect bother is observed early in the course of treatment, and signals an opportunity to develop interventions to promote treatment adherence."

Adverse events • Journal • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Melanoma • Multiple Myeloma • Oncology • Solid Tumor

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Ruth O'Regan | Trial completion date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Bireociclib plus letrozole/anastrozole versus placebo plus letrozole/anastrozole for the treatment of HR+/HER2- advanced breast cancer: Interim analysis of BRIGHT-3 study (ESMO 2025) - P3 | "In bireociclib group, the most common TEAEs were diarrhea [93.5% (all grades); 8.4% (≥grade 3)], neutropenia [78.7%; 29.3%], and anemia [61.6%; 6.1%]. Conclusions Bireociclib plus letrozole/anastrozole significantly prolonged PFS for patients with HR+/HER2- ABC as first or second-line therapy with well-tolerated toxicity."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2

Efficacy and safety outcomes across young to older age groups of patients with HR+/HER2 - advanced breast cancer treated with bireociclib plus endocrine therapy: A pooled analysis of BRIGHT studies (ESMO 2025) - P1/2, P3 | "The pts received bireociclib plus anastrozole/letrozole/fulvestrant or anastrozole/letrozole/fulvestrant alone as allocated and prespecified in the protocol. Treatment discontinuation due to TEAE was reported in 1.9% pts aged <65y with BE, 0.5% pts aged <65y with ET alone, 5.5% pts aged ≥65y with BE, 2.4% pts aged ≥65y with ET alone. Conclusions Bireociclib plus ET is an effective, well-tolerated treatment for elderly pts with HR+/Her2- ABC as first or second-line endocrine therapy."

Metastases • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2